Abstract: [Objective]To investigate the clinical effects of parathyroid hormone for osteoporotic vertebral compressed fractures after vertebroplasty. [Methods]We selected from patients with osteoporotic vertebral compressed fractures in our hospital in January 2019 to June 2019, divided into two groups, including control group, a total of 40 cases treated with percutaneous vertebroplasty and postoperative taking calcium and vitamin D. Study group, a total of 30 cases, in addition to control group, accepted no less than 6 months of the parathyroid hormone treatment. Pain and function of life (VAS,ODI) were compared in different stages. And the bone mineral density was detected. The incidence of refracture was closely followed up. The data was compared with Student’s T-test or ANOVA. [Result] Both groups got less VAS and ODI scores after surgery treatment, and the scores further reduced three months later. But no significant difference between two groups was found in VAS scores either before or after the treatment until six month, when study group had statistic difference compared with control group. Since three month after the treatment，study group had lower scores in ODI than control group. Bone mineral density of the study group also increased with statistical differences at six month. The study group had significantly lower rate of refracture of the vertebra than the control group with statistically difference. [Conclusion] Parathyroid hormone for patients with osteoporotic vertebral compressed fractures after vertebroplasty can more effectively relieve pain, improve the function of life, and increase bone mineral density, reduce the risk of refractures.